Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
6 participants
INTERVENTIONAL
2018-07-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
AIM3: The purpose of Aim-3 of this study is to determine the role of basal GLP-1 action on fasting glucose regulation in lean, obese, pre-diabetic and type 2 diabetic (T2DM) subjects. A cross sectional study of age-matched subjects across the spectrum of glucose tolerance will be used to test the hypothesis that fasting GLP-1 action increases as beta-cell function declines.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll up to 20-25 healthy participants and while it is anticipated that the screening blood draw will yield a number of screen failures, it is estimated that 10-15 subjects will complete the entire study protocol. Enrolled participants will be asked to complete three study visits including the consent visit and two infusion study visits that will include hyperglycemic clamp procedures with the addition of the GLP-1 receptor antagonist Exendin (9-39) to determine the fasting GLP-1 effect. Each infusion procedure will last 2 hours. Subjects will be asked to take dexamethasone daily for approximately one week between Visit-2 and Visit-3 to induce insulin resistance.
The investigators will enroll 6-10 additional subjects as controls for effects of time and repeat testing. These individuals will have identical clamps with no dexamethasone at approximately 1 week intervals and will be determined at random by study staff.
The primary outcome for visits 2-3 will be to measure the effects of Ex-9 on fasting glucose-stimulated insulin secretion before and after experimentally induced insulin resistance. The primary experimental variable for analysis will be C-peptide during the clamp. Mean values will be compared between the period of glucose only stimulation and glucose with Ex-9. For each subject in the active treatment arm data will be analyzed using 2-way ANOVA for repeated measures using time (0-60 vs 60-120 min) and treatment (Dex vs no Dex) as the two factors. Based on the investigators' previous studies the investigators expect a significant time effect due to Ex-9. If there is an interaction with treatment the investigators would conclude that experimental insulin resistance influences the fasting GLP-1 effect. Data from control subjects will be analyzed identically; here the investigators expect no interaction, indicating that the fasting GLP-1 is a stable measure. In the investigators' previous study using Ex-9 during a glucose clamp, the average coefficient of variation in insulin concentrations at the conclusion of each step in the ramp was 30%. Using this estimate of between subject variation, detecting a 20% difference between subsequent steps in the GLP-1 ramp with a power of 80% and significance level of 0.05 will require 8 subjects.
AIM3: The purpose of Aim-3 of this study is to determine the role of basal GLP-1 action on fasting glucose regulation in lean, obese, pre-diabetic and type 2 diabetic (T2DM) subjects. Approximately 15-20 subjects will complete this cross sectional study of age-matched subjects across the spectrum of glucose tolerance will be used to test the hypothesis that fasting GLP-1 action increases as beta-cell function declines.
Enrolled participants for Aim-3 will be asked to complete two study visits including the consent visit and one infusion visit that will include a hyperglycemic clamp and an infusion of the antagonist Exendin (9-39). The infusion procedure will last approximately 2 hours.
The primary outcome measure for Aim-3 will be the fasting GLP-1 effect. This will be defined as the difference in steady state glucose-stimulated insulin secretion with and without Ex-9. The difference will be expressed as a percentage of glucose stimulated insulin secretion without Ex-9, and serve as the primary variable for comparison among the lean, obese and diabetic cohorts.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hyperglycemic clamp + Exendin (9-39)
During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
Exendin (9-39)
Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
Hyperglycemic Clamp
A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
Dexamethasone
Subjects will be asked to take 4 mg once daily between Visit-2 and Visit-3.
Dexamethasone
Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exendin (9-39)
Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
Dexamethasone
Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
Hyperglycemic Clamp
A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy adults age 20-45 years
* Body Mass Index (BMI) less than or equal to 35.0 kg/m2
* HbA1c less than or equal to 5.7% as measured at screening visit
* Ability to speak and understand English
AIM3: NON-DIABETIC SUBJECTS
* Adults age 18-65 years
* Body Mass Index (BMI) 25-40.0 kg/m2
* HbA1c less than or equal to 6.5% as measured at screening visit
* No Diabetes or use of diabetes medications such as insulin or metformin
* Ability to speak and understand English
AIM3: DIABETIC Type II SUBJECTS
* Adults age 18-65 years
* Body Mass Index (BMI) 25-40.0 kg/m2
* HbA1c less than or equal to 7.5% plus a diagnosis of Type II diabetes managed by either Metformin, Sulfonylurea, or diet and exercise
* Ability to speak and understand English
Exclusion Criteria
* Uncontrolled high blood pressure
* Diabetes or use of diabetes medications such as insulin or metformin
* Evidence of active heart disease, unstable angina or heart failure
* Lung disease or COPD
* Malabsorptive GI disease, such as celiac disease, or gastric bypass
* Significant hepatic disease
* Kidney disease or renal insufficiency (eGFR \< 60 mL/kg/min)
* Untreated anemia (hematocrit \< 34%) as measured at screening visit
* Pregnant females
* Active substance abuse
* Chronic use of oral steroid medications such as prednisone and hydrocortisone
* Apparent sensitivity to any study peptides as determined by the skin test
* Diagnosis or h/o PTSD
* Active mental health disorders such as depression, or as a result of Traumatic Brain Injury (TBI)
AIM3: ALL SUBJECTS
* Uncontrolled high blood pressure
* Evidence of active heart disease, unstable angina or heart failure
* Lung disease or COPD
* Malabsorptive GI disease, such as celiac disease, or gastric bypass
* Significant hepatic disease
* Kidney disease or renal insufficiency (eGFR \< 60 mL/kg/min)
* Untreated anemia (hematocrit \< 34%) as measured at screening visit
* Pregnant females
* Active substance abuse
* Chronic use of oral steroid medications such as prednisone and hydrocortisone
* Apparent sensitivity to any study peptides as determined by the skin test
* Diagnosis or h/o PTSD
* Active mental health disorders such as depression, or as a result of Traumatic Brain Injury (TBI)
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Durham VA Medical Center
FED
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David D'Alessio, MD
Role: PRINCIPAL_INVESTIGATOR
Durham VA Medical Center, Durham, NC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Durham VA Medical Center, Durham, NC
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00070325
Identifier Type: OTHER
Identifier Source: secondary_id
01992
Identifier Type: OTHER
Identifier Source: secondary_id
ENDA-006-15S
Identifier Type: -
Identifier Source: org_study_id